BRAF and thyroid gland carcinoma: Furthermore, TERT mutations have been shown to enhance the prognostic effects of coexisting BRAF or RAS mutations in differentiated thyroid cancer patients, strengthening risk prediction models and providing valuable insights into the clinical management of thyroid malignancies 37.